ArticleMolecular and cellular biochemistry2026
SENP1 regulates the malignant activities of osteosarcoma cells and antitumor immunity via the cGAS-STING signaling.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is an aggressive bone malignancy with poor prognosis. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is critical in anti-tumor immunity, its regulation in osteosarcoma remains unclear. Through UALCAN database screening, we identified elevated SUMO-specific protease 1 (SENP1) expression in sarcoma tissues, but whether it affects STING pathway remains unclear. Although other SENP family members (such as SENP2 and SENP6) have been implicated in immune regulation, their direct role in STING deSUMOylation within the osteosarcoma is limited. Herein, we explore how SENP1 (SUMO-specific protease 1) influences osteosarcoma progression and anti-tumor immunity by modulating the cGAS-STING pathway. SENP1 expression was preliminary analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) webserver and The Cancer Genome Atlas (TCGA) dataset, and further verified by western blot. Cell malignant activities were determined by functional assays Specific protein expressions were analyzed by western blot and immunohistochemistry. The mechanism of SENP1 regulating cGAS-STING pathway was validated by immunoprecipitation (IP) and co-immunoprecipitation (Co-IP) assays. In vivo experiments were finally conducted to verify the function of SENP1. The expression of SENP1 was markedly elevated in osteosarcoma cell lines. SENP1 silencing markedly suppressed the proliferation, migration, and invasion of U2OS and MG63 cells. Additionally, SENP1 silencing upregulated cGAS and STING protein levels. Mechanistically, SENP1 interacted with cGAS and regulated its SUMOylation status. The inhibitory effects of SENP1 knockdown on osteosarcoma cell proliferation, migration, and invasion, as well as its promotive effects on CD8+ T cell migration and the secretion of cytotoxic factors (IFN-γ, GZMB, and IL-2), were significantly reversed by concomitant cGAS depletion. In vivo, SENP1 deficiency inhibited tumor growth in xenograft models, activated the cGAS-STING pathway, and enhanced CD8+ T cell-mediated cytotoxicity. SENP1 silencing restrains osteosarcoma cell proliferation, migration, invasion and facilitates anti-tumor immunity via activation of the cGAS-STING signaling.
Indexed as
Identifiers
42048030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.